Chardan Capital Reiterates a Buy Rating on Crispr Therapeutics AG (CRSP)

In a report released today, Geulah Livshits from Chardan Capital reiterated a Buy rating on Crispr Therapeutics AG (CRSPResearch Report), with a price target of $72.50. The company’s shares closed last Monday at $49.64, close to its 52-week high of $53.97.

According to TipRanks.com, Livshits is a 3-star analyst with an average return of 6.2% and a 51.9% success rate. Livshits covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics Inc, Logicbio Therapeutics Inc, and Intellia Therapeutics.

Crispr Therapeutics AG has an analyst consensus of Strong Buy, with a price target consensus of $69.56.

See today’s analyst top recommended stocks >>

Based on Crispr Therapeutics AG’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $53.7 million. In comparison, last year the company had a GAAP net loss of $38.38 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, and Shaun Patrick Foy in 2014 and is headquartered in Zug, Switzerland.